Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin.
Leung
A Y H
AY
Liang
R
R
D000368:Aged; D000617:Aminoglycosides / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000079982:Gemtuzumab; D006801:Humans; D016756:Immunoglobulins, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy*
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D000079982:Gemtuzumab